Detalhe da pesquisa
1.
Methylation of the chromatin modifier KMT2D by SMYD2 contributes to therapeutic response in hormone-dependent breast cancer.
Cell Rep
; 43(5): 114174, 2024 May 28.
Artigo
em Inglês
| MEDLINE | ID: mdl-38700982